Melissa H.S. Hillebrandt-Roeffen

Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent

Anke van Erp, Yvonne M.H. Versleijen‐Jonkers, Melissa H.S. Hillebrandt-Roeffen et al. · Oncotarget · 2017 · 98 citations · Full text

Life Sciences, Immunology, Oncology +17

Next generation sequencing in synovial sarcoma reveals novel gene mutations

Myrella Vlenterie, Melissa H.S. Hillebrandt-Roeffen, Uta Flucke et al. · Oncotarget · 2015 · 64 citations · Full text

Medicine, Genetics, Oncology +15

The role of AXL and the <i>in vitro</i> activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma

Emmy D.G. Fleuren, Melissa H.S. Hillebrandt-Roeffen, Uta Flucke et al. · Oncotarget · 2014 · 47 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas

Marije E. Weidema, Ellen van de Geer, Christian Koelsche et al. · Clinical Cancer Research · 2019 · 41 citations

Medicine, Genetics, Oncology +17

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib

Anke van Erp, Melissa H.S. Hillebrandt-Roeffen, Laurens van Houdt et al. · Targeted Oncology · 2017 · 39 citations · Full text

Medicine, Oncology, Pharmacology +17